Beyond Hospital Pre-Merger Notice: PESP Report Reveals States Are Targeting Private Equity Control via MSOs, Debt, and Sale-Leasebacks

The Private Equity Stakeholder Project released its 2026 State Healthcare Policy Review documenting an accelerating regulatory response to private equity's expanding footprint in U.S. healthcare. As of August 2026, six states had enacted nine distinct oversight laws designed to constrain PE control across hospital networks and ancillary healthcare operations. The legislative momentum reflects growing state concern over the scale and structure of PE healthcare investments: in 2025 alone, PE firms executed 1,029 healthcare transactions, now owning more than 550 hospitals representing nearly one-eighth of all private, non-government U.S. hospitals, and operating over 500 additional facilities through joint ventures with non-profit health systems.

The report identifies a critical shift in state regulatory strategy. Rather than limiting oversight to straightforward hospital change-of-ownership notices, states are now targeting the structural mechanisms PE firms use to maintain control while avoiding traditional regulatory scrutiny. These indirect levers include management services organizations (MSOs) that provide administrative and clinical oversight, debt-financed dividend recapitalizations that extract cash while leveraging provider assets, REIT-structured sale-leasebacks that separate real estate ownership from operations, and parent holding company arrangements that concentrate control upstream from regulated hospital entities.

California's implementation of AB 1415 in 2026 exemplifies this evolving regulatory approach. The statute expanded pre-closing notice requirements to encompass PE groups, hedge funds, MSOs, and provider holding entities, directing all notifications to the Office of Health Care Affordability for mandatory review before transaction finality. This framework attempts to unmask upstream ownership structures and contractual relationships that historically operated outside regulatory purview. The law represents a transparency-first strategy that gives state regulators visibility into deal architecture before commitments become irreversible, creating leverage to challenge structures deemed contrary to state healthcare policy objectives.

The concentration of legislative activity in six states—with California and Oregon leading through 2025 statutory implementations, and smaller states following suit through 2026—suggests emerging market bifurcation in PE healthcare investing. States with active oversight regimes now impose material transaction costs and timeline extensions, potentially redirecting PE capital toward less-regulated jurisdictions or structurally simpler deal types. For institutional investors and hedge funds with healthcare sector exposure, the PESP report underscores the regulatory risk embedded in PE-backed healthcare platforms, particularly those dependent on MSO arrangements, leveraged recapitalizations, or real estate monetization strategies.